Journal
ACS NANO
Volume 17, Issue 1, Pages 382-401Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.2c08706
Keywords
upconversion nanoparticles; folate-targeted liposome; Fenton-based therapy; nanoreactors; oxidative stress; immunogenic ferroptosis
Ask authors/readers for more resources
By combining the UV-catalyzed Fenton reaction and the chemotherapeutic agent cisplatin, an upconversion luminescence-fueled nanoreactor has been developed for the treatment of triple negative breast cancer. The nanoplatform can emit UV photons to convert Fe3+ to Fe2+ for the generation of hydroxyl radicals, leading to the induction of ferroptosis and apoptosis. A folate receptor targeted liposome coating layer has been used for high biocompatibility and targeted delivery, resulting in superior antitumor efficacy with minimal side effects.
As an emerging anticancer strategy, ferroptosis has recently been developed in combination with current therapeutic modalities to overcome the existing limitations of conventional therapies. Herein, an ultraviolet (UV) upconversion luminescence-fueled nanoreactor is explored to combine ferroptosis and apoptosis through the UV-catalyzed Fenton reaction of an iron supplement (ferric ammonium citrate) loaded in a mesoporous silica layer in addition to the support of a chemotherapeutic agent (cisplatin) attached on the functionalized silica surface for the treatment of triple negative breast cancer (TNBC). The nanoplatform can circumvent the low penetration depth typical of UV light by upconverting near infrared irradiation and emitting UV photons that convert Fe3+ to Fe2+ to boost the generation of hydroxyl radicals (center dot OH), causing devastating lipid peroxidation. Apart from DNA damage-induced apoptosis, cisplatin can also catalyze Fenton-based therapy by its abundant production of hydrogen peroxide (H2O2). As a bioinspired lipid membrane, the folate receptor targeted liposome as the coating layer offers high biocompatibility and colloidal stability for the upconversion nanoparticles, in addition to prevention of the premature release of encapsulated hydrophilic compounds, before driving the nanoformulation to the target tumor site. As a result, superior antitumor efficacy has been observed in a 4T1 tumor-bearing mouse model with negligible side effects, suggesting that such a nanoformulation could play a pivotal role in effective apoptosis-strengthened ferroptosis TNBC therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available